Company intelligence / Profile preview

MIG Capital

Munich, Bavaria, Germany

Ownership: Private
Development stage: Other

Overview

MIG Capital is a leading German venture capital firm, focused on early and mid-stage investments in life sciences (especially biopharmaceuticals and medical technology) and deep tech areas. It does not itself run clinical trials or therapeutics, but it backs innovative companies advancing new modalities and platforms, including antibodies, mRNA-based drugs, small molecules, and more through its portfolio companies[6][10][8].

Industry: Investors

Partnerships

Portfolio company partnerships, such as with SciRhom (autoimmune antibody therapies)[1][5]Portfolio company partnerships with BioNTech (cancer immunotherapy, mRNA therapeutics)[3]Partnership with ASTRA Therapeutics (precision anti-parasitic drugs, veterinary health)[7][9]

Beyond the preview

Go deeper on MIG Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIG Capital.

Explore the full profile